Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis

J Dermatol. 2014 Aug;41(8):746-8. doi: 10.1111/1346-8138.12563. Epub 2014 Jul 16.

Abstract

Matrix metalloproteinase-13 (MMP-13), a member of the collagenase family, has been implicated in the pathogenesis of connective tissue diseases characterized by extracellular matrix remodeling. Since serum MMP-13 levels reflect disease severity of systemic sclerosis and localized scleroderma, we evaluated the clinical significance of serum MMP-13 levels in eosinophilic fasciitis (EF). All the EF patients had serum MMP-13 levels lower than the mean - 2SD of healthy controls. Serum MMP-13 levels were also significantly decreased in EF patients compared with diffuse cutaneous systemic sclerosis, limited cutaneous systemic sclerosis, and generalized morphea patients. Although serum MMP-13 levels did not reflect any clinical and serological features of EF, these results indicate that MMP-13 may be involved in the development of this disease.

Keywords: eosinophilic fasciitis; extracellular matrix; fibrosis; matrix metalloproteinase-13; scleroderma.

MeSH terms

  • Case-Control Studies
  • Eosinophilia / blood
  • Eosinophilia / enzymology*
  • Eosinophilia / etiology
  • Fasciitis / blood
  • Fasciitis / enzymology*
  • Fasciitis / etiology
  • Humans
  • Matrix Metalloproteinase 13 / blood*
  • Scleroderma, Diffuse / enzymology
  • Scleroderma, Limited / enzymology
  • Scleroderma, Localized / enzymology
  • Scleroderma, Systemic / enzymology

Substances

  • MMP13 protein, human
  • Matrix Metalloproteinase 13

Supplementary concepts

  • Eosinophilic Fasciitis